Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AHPI > SEC Filings for AHPI > Form 10-Q on 10-May-2013All Recent SEC Filings

Show all filings for ALLIED HEALTHCARE PRODUCTS INC | Request a Trial to NEW EDGAR Online Pro

Form 10-Q for ALLIED HEALTHCARE PRODUCTS INC


10-May-2013

Quarterly Report


Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Medical Device Excise Tax

Under the Health Care Education Reconciliation Act of 2010(the "Act"), beginning on January 1, 2013, a Medical Device Excise Tax ("MDET") is imposed on all U.S. sales of certain medical devices. The tax is 2.3% of the selling price of the taxable product, subject to certain exceptions. The MDET will represent an additional cost burden on the Company's operations. The MDET for the three months ended March 31, 2013 was approximately $70,000. The Company intends to mitigate the effect of the MDET through a combination of anticipated increases in market prices, by improving operational efficiency, and the increased access to healthcare anticipated by the Act. However, the Company does not have any assurance that these strategies will be successful in entirely offsetting the cost of the MDET.

Results of Operations

Three months ended March 31, 2013 compared to three months ended March 31, 2012

Allied had net sales of $9.2 million for the three months ended March 31, 2013, down $1.5 million from net sales of $10.7 million in the prior year same quarter. Domestic sales were down 11.2% while international sales, which represented 22.1% of third quarter sales, were down 22.5% from the prior year same quarter.

Sales for the three months ended March 31, 2013 and 2012 included $-, and $172,050, respectively, for the recognition of income from payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of BaralymeŽ. Income from the agreement was recognized at $57,350 per month until the expiration of the agreement in August 2012. Allied continues to sell CarbolimeŽ, a carbon dioxide absorbent with a different formulation than BaralymeŽ, as well as LitholymeŽ, a new premium carbon dioxide absorbent. The Company ceased the sale of BaralymeŽ on August 27, 2004.

Orders for the Company's products for the three months ended March 31, 2013 of $9.1 million were $1.5 million or 14.2% lower than orders for the prior year same quarter of $10.6 million. Domestic orders are down 7.9% over the prior year same quarter while international orders, which represented 19.2% of third quarter orders, were 33.2% lower than orders for the prior year same quarter. The decrease in domestic orders includes a decrease in construction market demand. The Company continues to believe that the purchase of equipment and durable goods and the purchase of equipment by hospitals and municipalities have been cut to meet budgets and conserve cash due to the slow recovery of the economy since the recession in 2008. Orders and sales remain below pre-recession levels. The decrease in international orders reflects fluctuation in international demand and order levels, but the Company does not believe this decrease indicates a drop in market share.

Gross profit for the three months ended March 31, 2013 was $1.7 million, or 18.5% of net sales, compared to $2.3 million, or 21.5% of net sales, for the three months ended March 31, 2012. The $0.6 million reduction in gross profit is primarily attributable to the decrease in sales and production. Gross profit, as a percentage of sales, was negatively impacted by the $172,050 reduction in payments resulting from the Abbott agreement recognized in sales and income. In addition, lower sales have led to lower utilization of fixed expenses in the Company's manufacturing operations. Gross profit for the three months ended March 31, 2013 was also negatively impacted by approximately $70,000 as a result of the MDET. Under the Act, beginning on January 1, 2013, a MDET is imposed on all U.S. sales of certain medical devices. The tax is 2.3% of the selling price of the taxable product, subject to certain exceptions.

Selling, general and administrative expenses for the three months ended March 31, 2013 were $2.6 million unchanged from the same quarter a year ago. Salaries and benefits were approximately $164,000 higher than in the prior year and travel expenses were approximately $110,000 higher than in the prior year. These increases have been offset by a decrease in other expense accounts including a $96,000 decrease in legal expenses, a $31,000 reduction in recruiting expenses, and an approximately $40,000 decrease in outside engineering consulting charges.

Loss from operations was $960,423 for the three months ended March 31, 2013 compared to loss from operations of $230,535 for the three months ended March 31, 2012. Other income and expenses for the nine months ended March 31, 2013 include approximately $516,000 of income to the Company as a result of the demutualization of the Company's product liability insurer. This income was a one-time event.

Allied had a loss before benefit from income taxes in the third quarter of fiscal 2013 of $450,131 compared to a loss before benefit from income taxes in the third quarter of fiscal 2012 of $235,140. The Company recorded a tax benefit of $171,050 for the three months ended March 31, 2013 compared to a tax benefit of $89,353 for the three months ended March 31, 2012.

Net loss for the third quarter of fiscal 2013 was $279,081 or $0.03 per basic and diluted share compared to net loss of $145,787 or $0.02 per basic and diluted share for the third quarter of fiscal 2012. Net loss for the 2013 period includes the one-time payment related to the demutualization of the Company's product liability insurer. The weighted average number of common shares outstanding, used in the calculation of basic and diluted earnings per share for the third quarters of fiscal 2013 and 2012 were 8,029,076 and 8,124,386, respectively.

Nine months ended March 31, 2013 compared to nine months ended March 31, 2012

Allied had net sales of $28.4 million for the nine months ended March 31, 2013, down $4.4 million, or 13.4% from net sales of $32.8 million in the prior year same period resulting from lower order levels. Domestic sales were down 17.7% from the prior year same period while international sales were up 2.5% from the prior year same period. International business represented 25.5% of sales for the first nine months of fiscal 2013.

Sales for the nine months ended March 31, 2013 and 2012 included $114,700 and $516,150 respectively for the recognition of income of payments resulting from the agreement with Abbott Laboratories to cease the production and distribution of BaralymeŽ. Income from the agreement was recognized at $57,350 per month until the expiration of the agreement in August 2012.

Orders for the Company's products for the nine months ended March 31, 2013 of $28.0 million were $3.3 million or 10.5% lower than orders for the prior year same period of $31.3 million. Domestic orders are down 11.7% over the prior year same period while international orders, which represented 24.8% of orders for the first nine months of fiscal 2013, were 6.7% lower than orders for the prior year same period. The decrease in domestic orders includes a decrease in construction market demand. The decrease in domestic orders is also partially the result of a decrease in government orders from the prior year. The Company believes the drop in government spending is due to budget negotiations and constraints. The Company believes this is a fluctuation in government orders generally and does not represent a decrease in the Company's market share. The decrease in international orders reflects fluctuation in international demand and order levels, but the Company does not believe this decrease indicates a drop in market share.

Gross profit for the nine months ended March 31, 2013 was $5.8 million, or 20.4% of net sales, compared to $7.5 million, or 22.9% of net sales, for the nine months ended March 31, 2012. The decrease in gross profit is primarily the result of lower sales and production levels, including the decrease in income recognized from the agreement with Abbott Laboratories, than in the prior year. Lower sales and production levels result in lower utilization of fixed overhead expenses. Gross profit for the nine months ended March 31, 2013 was also negatively impacted by approximately $70,000 as a result of the 2.3% MDET imposed on all U.S. sales of certain medical devices. Gross profit during the first nine months was favorably impacted from the prior year by an approximately $0.4 million reduction in shipping and other startup cost at its Stuyvesant Falls facility. Gross Profit during the first nine months of fiscal 2013 was also favorably impacted by approximately $0.2 million in cost reductions for purchased materials and manufacturing processes at the Company's St. Louis facility.

Selling, general and administrative expenses for the nine months ended March 31, 2013 were $8.1 million compared to selling, general and administrative expenses of $7.9 million for the nine months ended March 31, 2012. Salaries and benefits are approximately $437,000 higher than in the prior year, as a result of less employee turnover and higher medical benefit payments. In addition travel expense is approximately $220,000 higher related to the Company's efforts to increase direct sales contact and efforts. These increases have been partially offset by decreases in other expense accounts including a $187,000 decrease in legal expenses and a $91,000 decrease in recruiting expenses.

Loss from operations was $2.4 million for the nine months ended March 31, 2013 compared to loss from operations of $0.4 million for the nine months ended March 31, 2012. Other income and expenses for the nine months ended March 31, 2013 include approximately $516,000 received by the Company as a result of the demutualization of the Company's product liability insurer which was a one-time event.

Allied had loss before benefit from income taxes in the first nine months of fiscal 2013 of $1.9 million, compared to loss before benefit from income taxes in the first nine months of fiscal 2012 of $432,361. The Company recorded a tax benefit of $710,236 for the nine months ended March 31, 2013 compared to a tax benefit of $164,297 for the nine months ended March 31, 2012.

Net loss for the nine months ended March 31, 2013 was $1,158,806 or $0.14 per basic and diluted share compared to net loss of $268,064 or $0.03 per basic and diluted share for the first nine months of fiscal 2012. Net loss for the 2013 period includes the effect of the one-time payment related to the demutualization of the Company's product liability insurer. The weighted average number of common shares outstanding, used in the calculation of basic and diluted earnings per share for the first nine months of fiscal 2013 and 2012 were 8,085,091 and 8,124,386, respectively.

Liquidity and Capital Resources

The Company believes that available resources, including availability under a credit facility described below, are sufficient to meet operating requirements in the coming year.

The Company's working capital was $14.0 million at March 31, 2013 compared to $16.0 million at June 30, 2012. The decrease in working capital was primarily a result of accounts receivable which decreased by $1.4 million largely due to a decrease in sales. Accounts receivable as measured in days of sales outstanding ("DSO") was 36 DSO at March 31, 2013; down from 44 DSO at June 30, 2012. In addition cash and cash equivalents decreased by $1.0 million. At March 31, 2013 these decreases in working capital were offset by an increase in other current assets of $0.1 million and a decrease in accounts payable of $0.5 million. The increase in other current assets is a result of prepayment of the Company's insurance premiums for the fiscal year.

The Company is party to a Loan and Security Agreement, dated November 17, 2009, with Enterprise Bank & Trust (the "Credit Agreement") pursuant to which the Company has a secured revolving credit facility with borrowing availability of up to $5,000,000 (the "Credit Facility"). The Company's obligations under the Credit Facility are secured by certain assets of the Company pursuant to the terms and subject to the conditions set forth in the Credit Agreement. See Note
5 - Financing to the Company's unaudited financial statements for more information concerning the Credit Facility.

Advances under the Credit Facility will be made pursuant to a Revolving Credit Note executed by the Company in favor of Enterprise Bank & Trust. Such advances will bear interest at a rate equal to the 30-day LIBOR rate plus 3.50%. Advances may be prepaid in whole or in part without premium or penalty. The 30-day LIBOR rate was 0.20% on March 31, 2013.

At March 31, 2013 the Company had no aggregate indebtedness, including capital lease obligations, short-term debt and long term debt.

In the event that economic conditions were to severely worsen for a protracted period of time, we believe that we will have borrowing capacity under credit facilities that will provide sufficient financial flexibility. The Company would have options available, including postponing capital expenditures, to ensure liquidity in addition to increased borrowing.

Inflation has not had a material effect on the Company's business or results of operations during the first nine months of fiscal 2013.

Litigation and Contingencies

The Company becomes, from time to time, a party to personal injury litigation arising out of incidents involving the use of its products. The Company believes that any potential judgments resulting from these claims over its self-insured retention will be covered by the Company's product liability insurance.

Recently Issued Accounting Guidance

The impact and any associated risks related to the Company's critical accounting policies on business operations are discussed throughout "Management's Discussion and Analysis of Financial Condition and Results of Operations," where such policies affect the Company's reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see the Company's Annual Report on Form 10-K for the year ended June 30, 2012.

See Note 1 - Summary of Significant Accounting and Reporting Policies for more information on recent accounting pronouncements and their impact, if any, on the Company's financial statements. Management believes there have been no material changes to our critical accounting policies.

  Add AHPI to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AHPI - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.